文章詳情
                        
                        體內(nèi)轉(zhuǎn)染技術(shù)要點(diǎn)
日期:2025-04-03 22:34
            瀏覽次數(shù):546
        
            摘要:
 	
 		1.       質(zhì)粒的制備
 	
 	
 		體內(nèi)轉(zhuǎn)染對(duì)質(zhì)粒的要求更嚴(yán)格,建議使用高質(zhì)量的質(zhì)粒,無RNA污染,無內(nèi)**和低蛋白成分。質(zhì)粒的純度低會(huì)嚴(yán)重影響轉(zhuǎn)染的效率,雜質(zhì)和內(nèi)**的存在會(huì)造成一定的**原性和毒性,嚴(yán)重者造成動(dòng)物和人的死亡。
 	
 	
 		 
 	
 	
 		2.       葡萄糖稀釋液
 	
 	
 		我們推薦使用無菌的等離子的10% 葡萄糖溶液(W/V)制備in vivo jetPEI/DNA復(fù)合物(終濃度為5% 的葡萄糖溶液),因?yàn)樵跓o鹽或低鹽的條件下,才能形成穩(wěn)定的小顆粒復(fù)合物。
 	
 	
 		 
 	
 	
 		3.       以小鼠為例,介紹不同注射途徑時(shí)的轉(zhuǎn)染...
        
    
		1.       質(zhì)粒的制備
	
	
		體內(nèi)轉(zhuǎn)染對(duì)質(zhì)粒的要求更嚴(yán)格,建議使用高質(zhì)量的質(zhì)粒,無RNA污染,無內(nèi)**和低蛋白成分。質(zhì)粒的純度低會(huì)嚴(yán)重影響轉(zhuǎn)染的效率,雜質(zhì)和內(nèi)**的存在會(huì)造成一定的**原性和毒性,嚴(yán)重者造成動(dòng)物和人的死亡。
	
	
		2.       葡萄糖稀釋液
	
	
		我們推薦使用無菌的等離子的10% 葡萄糖溶液(W/V)制備in vivo jetPEI/DNA復(fù)合物(終濃度為5% 的葡萄糖溶液),因?yàn)樵跓o鹽或低鹽的條件下,才能形成穩(wěn)定的小顆粒復(fù)合物。
	
	
		3.       以小鼠為例,介紹不同注射途徑時(shí)的轉(zhuǎn)染情況。
	
| 
					 
						Tail vein injection
					 
				 | 
			
| 
					 
						DNA: 50 μg
					 
					
						in vivo-jetPEI?: 5-10 μl
					 
					
						N/P ratio: 5-10
					 
					
						Injection volume: 200-400 μl, 5% glucose
					 
					
						Method: The mouse is placed in a restainer and 70% ethanol
					 
					
						is applied on the tail in order to slightly swell the vein. Complexes in solution are injected into thetail vein over 10 sec, using a ? inch
					 
					
						26 gauge needle and a 1 ml syringe.
					 
					 | 
			
| 
				 
					Intracerebral injection (stereotaxic injection)
				 
			 | 
		
| 
				 
					DNA: 1 μg (for 8-12 week-old mice)
				 
				
					in vivo-jetPEI?: 0.12 μl
				 
				
					N/P ratio: 6
				 
				
					Injection volume: 5 μl, 5% glucose
				 
				
					Method: Single injection (5 μl) into either
				 
				
					lateral ventricle (0.2 mm posterior to the
				 
				
					bregma line, 1.1 mm lateral, and 2.2 mm
				 
				
					deep from the pial surface) to pentobarbital
				 
				
					anesthetized mice (65 mg/kg).
				 
				 | 
		
| 
				 
					Retro-orbital injection
				 
			 | 
		
| 
				 
					DNA: 40 μg
				 
				
					in vivo-jetPEI?: 6.4 μl
				 
				
					N/P ratio: 8
				 
				
					Injection volume: 200-400 μl, 5% glucose
				 
				
					Method: The tip of a 27 g hypodermic needle is introduced
				 
				
					carefully in front of the eye. Follow the edge of the orbit down until
				 
				
					feeling the needle tip at the base beneath the eye. Inject complexesin solution within 2 sec. If performed carefully, there will be little or
				 
				
					no bleeding. The capillary nexus will take up the injected solution
				 
				
					rapidly.
				 
			 | 
		
| 
				 
					Nasal instillation for trachea
				 
				
					and lung delivery
				 
			 | 
		
| 
				 
					DNA: 20 μg
				 
				
					in vivo-jetPEI?: 2-4 μl
				 
				
					N/P ratio: 5-10
				 
				
					Injection volume: 50-200 μl, 5% glucose
				 
				
					Method: Mice are held supine at an angle of 45° with pressure applied to the
				 
				
					lower mandibule to immobilize the tongue and prevent swallowing. Complexes
				 
				
					in solution are then introduced to the nasal planum using a micropipet.
				 
			 | 
		
| 
				 
					Intraperitoneal injection
				 
			 | 
		
| 
				 
					DNA: 100 μg
				 
				
					in vivo-jetPEI?: 16-20 μl
				 
				
					N/P ratio: 8-10
				 
				
					Injection volume:
				 
				
					400 μl to 1 ml, 5% glucose
				 
				
					Method: Complexes in solution
				 
				
					are injected into the peritoneal
				 
				
					cavity over 10 sec, using a ?
				 
				
					inch 26 gauge needle and a 1 ml
				 
				
					syringe.
				 
				 | 
		
| 
				 
					Intratumoral injection
				 
			 | 
		
| 
				 
					DNA: 10-20 μg
				 
				
					in vivo-jetPEI?: 1-4 μl
				 
				
					N/P ratio: 5-10
				 
				
					Injection volume: 50-100 μl, 5% glucose
				 
				
					Method: For implanted subcutaneous tumors
				 
				
					(size> 5 mm3), perform multiple injections of
				 
				
					10-20 μl complexes at different sites of the tumor to
				 
				
					avoid reflux.
				 
				 | 
		
    


